Parkinson’s hallucinations can often be reduced or managed through a combination of medication adjustments, treating underlying triggers, and changes to the home environment. Up to 60% of people with Parkinson’s disease experience some form of psychosis, most commonly visual hallucinations, and the approach to stopping them depends on what’s driving them. In many cases, the hallucinations aren’t caused by Parkinson’s itself getting worse but by medications, infections, poor sleep, or even poor lighting in the home.
Why Parkinson’s Causes Hallucinations
The brain normally balances what your eyes actually see with predictions based on past experience. In Parkinson’s, that balance breaks down. The brain’s “default mode network,” which is active during daydreaming and mind-wandering, becomes overactive, while the networks responsible for attention and accurate perception weaken. The result is that the brain over-interprets visual input, essentially filling in details that aren’t there and presenting them as real.
This isn’t a single-chemical problem. Visual processing depends on a complex interplay between dopamine, serotonin, acetylcholine, and other signaling systems, and Parkinson’s disease disrupts all of them over time. The medications used to treat Parkinson’s motor symptoms, particularly levodopa and dopamine agonists, further tip this balance. Hallucinations tend to increase with higher doses and longer duration of treatment.
Check for Treatable Triggers First
When hallucinations appear suddenly or get noticeably worse, the first step is looking for a medical cause outside of Parkinson’s itself. Urinary tract infections are one of the most common culprits. UTIs are a leading cause of delirium and acute neurological deterioration in people with Parkinson’s, and systemic infections account for roughly 25% of all motor and cognitive flare-ups. Pneumonia is another frequent trigger. A simple course of antibiotics can sometimes resolve hallucinations that seemed alarming.
Dehydration, constipation, sleep deprivation, and new medications (including over-the-counter sleep aids or pain relievers) can also trigger or worsen hallucinations. Ruling these out is faster and safer than adjusting Parkinson’s medications, so it’s typically the right place to start.
Adjusting Parkinson’s Medications
Reducing or reorganizing Parkinson’s drugs is the most common first-line treatment for hallucinations. Because many of these medications increase dopamine activity in the brain, they can push the visual system toward misperception. The standard approach is to taper medications in a specific order, removing the ones most likely to cause hallucinations and least essential for movement first:
- Anticholinergics are removed first, as they contribute to confusion and have the least motor benefit in later-stage disease.
- Amantadine is next.
- MAO-B inhibitors follow.
- Dopamine agonists are then reduced or stopped. These carry higher rates of hallucinations than levodopa.
- COMT inhibitors come next.
- Levodopa is adjusted last, since it remains the most effective treatment for Parkinson’s motor symptoms.
The goal is to find the lowest effective dose that controls tremor and stiffness without triggering hallucinations. This is always a balancing act, and changes should be made gradually under medical supervision to avoid sudden worsening of movement symptoms.
Medications That Treat the Hallucinations Directly
When adjusting Parkinson’s drugs isn’t enough, a medication specifically targeting the hallucinations may be added. Pimavanserin (brand name Nuplazid) is the only FDA-approved drug for Parkinson’s disease psychosis. It works by blocking a specific serotonin receptor involved in visual misperception, without blocking dopamine, which means it doesn’t worsen motor symptoms the way older antipsychotics do.
In clinical trials, about 14% of patients on pimavanserin had a complete resolution of hallucinations and delusions at six weeks, compared to just 1% on placebo. More broadly, 74% of patients showed at least some measurable improvement, versus 54% on placebo. The standard dose is 34 mg once daily, taken without any need for gradual dose increases.
Two other options are considered when pimavanserin doesn’t work well enough. Clozapine is rated as “clinically useful” by the Movement Disorder Society but requires regular blood monitoring because of a rare but serious risk of lowering white blood cell counts. Quetiapine is rated as “possibly useful” and doesn’t require specialized monitoring, which makes it more practical for many patients, though its evidence base is weaker.
Why Most Antipsychotics Are Dangerous in Parkinson’s
This is one of the most important things to understand. Standard antipsychotics, the kind commonly prescribed for psychosis in other conditions, carry serious risks for people with Parkinson’s. A large study found that antipsychotic use in Parkinson’s patients was associated with more than double the risk of death within six months compared to no antipsychotic use. Haloperidol carried the highest risk, with a five-fold increase. Olanzapine and risperidone also showed significantly elevated mortality. Even quetiapine, the safest of the commonly used atypical antipsychotics, still carried a roughly two-fold increase in mortality risk.
Older “typical” antipsychotics also block dopamine receptors and can dramatically worsen Parkinson’s motor symptoms, sometimes causing a crisis. The Movement Disorder Society advises against using any antipsychotic other than pimavanserin, clozapine, or quetiapine for Parkinson’s psychosis.
Improving Vision and Lighting
Because Parkinson’s hallucinations stem partly from the brain over-interpreting incomplete visual information, anything that makes visual input clearer can help reduce their frequency. Correcting vision problems is a straightforward and often overlooked step. Cataract removal, updated eyeglass prescriptions, and treating conditions like macular degeneration have all been associated with reduced hallucinations. One study of patients with visual loss found that 23% saw improvement in hallucinations after treatment that restored some visual acuity.
Increasing indoor brightness also helps. Dim rooms and shadows give the brain more ambiguous input to misinterpret. Keeping living spaces well-lit, especially in the evening and during nighttime bathroom trips, reduces the visual “gaps” the brain tries to fill in.
Removing Visual Triggers at Home
Specific objects and patterns in the home can reliably trigger hallucinations. Case studies using photo assessments of patients’ living environments have identified common offenders: patterned carpets, clothing hanging on walls or doors, cushions arranged on sofas, and dolls or figurines. The brain misreads these as people, animals, or faces.
Practical changes that have worked for individual patients include putting away decorative cushions, covering patterned rugs with a plain tablecloth, storing hanging clothes inside closets rather than leaving them visible, and removing or covering dolls and figurines. These adjustments are simple and cost nothing, but they require someone to systematically look at the home through the lens of what might be visually ambiguous to someone whose brain is already prone to misperception.
The Role of Sleep
Sleep disturbances and hallucinations are closely linked in Parkinson’s. Hallucinations that occur around sleep, while falling asleep or waking up, are associated with longer disease duration, higher levodopa doses, more depressed mood, and higher scores on scales measuring REM sleep behavior disorder, a condition where people physically act out their dreams. Daytime hallucinations, by contrast, are more closely tied to overall disease severity.
Improving sleep quality can help on both fronts. This means addressing REM sleep behavior disorder if it’s present, treating restless leg syndrome, managing nighttime pain or stiffness, and maintaining consistent sleep-wake schedules. Depression, which worsens both sleep and hallucinations, is worth treating in its own right and may improve both.
What to Do During a Hallucination
If you’re caring for someone who is actively hallucinating, the most effective approach is calm, non-confrontational engagement. Arguing about whether the hallucination is real tends to increase distress without helping. Instead, acknowledge what the person is experiencing (“I can see that’s upsetting to you”) and gently redirect their attention. Turning on more lights, moving to a different room, or starting a simple activity can shift the brain’s focus away from the misperception.
It also helps to know that not all hallucinations require aggressive treatment. Early in the course of Parkinson’s psychosis, many people experience “minor” hallucinations: brief flashes of movement in peripheral vision, a sense of someone nearby, or fleeting images they recognize aren’t real. These “retained insight” hallucinations are less distressing and may only need monitoring. Treatment becomes more urgent when hallucinations are frequent, frightening, or when the person no longer recognizes them as unreal.